Evidence map›Paper›PMID 41446902›Full record

ArticleCase reports in women's health2026

Recurrent endometrial carcinoma with immune-mediated thrombocytopenia following durvalumab: A case report.

Ami Sakakibara, Shimpei Nagai, Terumi Shirane, Tomomi Sakai, Yoko Fujioka, Makiko Hino, Yoshihisa Hattori, Takashi Kurahashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ami SakakibaraDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Shimpei NagaiDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Terumi ShiraneDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Tomomi SakaiDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Yoko FujiokaDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Makiko HinoDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Yoshihisa HattoriDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Takashi KurahashiDepartment of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of immune checkpoint inhibitors (ICIs) has expanded the therapeutic landscape for advanced or recurrent endometrial carcinoma. Durvalumab-a programmed death-ligand 1 (PD-L1) inhibitor-demonstrated clinical benefit in the 2023 DUO-E trial when combined with carboplatin and paclitaxel. Immune thrombocytopenia (ITP) is an uncommon but potentially life-threatening immune-related adverse event (irAE). A 73-year-old woman with recurrent endometrial carcinoma developed severe ITP after three cycles of paclitaxel, carboplatin, and durvalumab. Fourteen days after cycle 3 she presented with pyelonephritis, bacteremia, and acute disseminated intravascular coagulation (DIC). Despite infection control, her platelet count declined to 1 × 10

Indexed as

DurvalumabEndometrial carcinomaImmune checkpoint inhibitorImmune-related adverse eventImmune thrombocytopenia

Identifiers

PMID41446902
PMCPMC12722021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.